Thus, PLK1 inhibition combined with Osimertinib decreases cell viability in EGFR-mutant NSCLC cells caused by further dampening of downstream EGFR signaling and apoptosis induction. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.